|
1
|
Defining the critical hurdles in cancer immunotherapy.
|
J Transl Med
|
2011
|
2.32
|
|
2
|
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".
|
J Transl Med
|
2008
|
1.77
|
|
3
|
Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome.
|
Clin Cancer Res
|
2005
|
1.68
|
|
4
|
Tumors as elusive targets of T-cell-based active immunotherapy.
|
Trends Immunol
|
2003
|
1.67
|
|
5
|
A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells.
|
Cancer Res
|
2003
|
1.63
|
|
6
|
Common cancer biomarkers.
|
Cancer Res
|
2006
|
1.56
|
|
7
|
Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation.
|
Transplantation
|
2012
|
1.52
|
|
8
|
The immunomodulatory capacity of mesenchymal stem cells.
|
Trends Mol Med
|
2011
|
1.47
|
|
9
|
Altered detoxification status and increased resistance to oxidative stress by K-ras transformation.
|
Cancer Res
|
2008
|
1.39
|
|
10
|
5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications.
|
Clin Cancer Res
|
2002
|
1.27
|
|
11
|
HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway.
|
Cancer Res
|
2004
|
1.26
|
|
12
|
Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity.
|
J Virol
|
2003
|
1.23
|
|
13
|
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas.
|
Proc Natl Acad Sci U S A
|
2008
|
1.18
|
|
14
|
B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response.
|
Clin Cancer Res
|
2011
|
1.17
|
|
15
|
Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines.
|
Int J Cancer
|
2004
|
1.17
|
|
16
|
The role of classical and non-classical HLA class I antigens in human tumors.
|
Semin Cancer Biol
|
2012
|
1.12
|
|
17
|
Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma?
|
J Urol
|
2004
|
1.10
|
|
18
|
Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines.
|
Clin Cancer Res
|
2011
|
1.04
|
|
19
|
T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2.
|
Int J Cancer
|
2010
|
1.03
|
|
20
|
Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma.
|
Cancer Res
|
2003
|
1.03
|
|
21
|
Melanoma-restricted genes.
|
J Transl Med
|
2004
|
1.03
|
|
22
|
MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma.
|
Int J Cancer
|
2004
|
1.01
|
|
23
|
HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.
|
J Immunol
|
2012
|
1.00
|
|
24
|
HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice.
|
Cancer Immunol Immunother
|
2008
|
1.00
|
|
25
|
Distinct molecular mechanisms leading to deficient expression of ER-resident aminopeptidases in melanoma.
|
Cancer Immunol Immunother
|
2010
|
1.00
|
|
26
|
Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention?
|
Cell Mol Life Sci
|
2010
|
0.98
|
|
27
|
Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival.
|
Cancer Res
|
2005
|
0.98
|
|
28
|
Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity.
|
Cancer Res
|
2006
|
0.97
|
|
29
|
Identification and validation of novel ERBB2 (HER2, NEU) targets including genes involved in angiogenesis.
|
Int J Cancer
|
2005
|
0.97
|
|
30
|
The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer.
|
J Immunol
|
2013
|
0.96
|
|
31
|
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".
|
J Transl Med
|
2013
|
0.95
|
|
32
|
Targeting of tumor associated antigens in renal cell carcinoma using proteome-based analysis and their clinical significance.
|
Proteomics
|
2002
|
0.94
|
|
33
|
Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8(+) T-cell infiltration in the tumor.
|
Int J Cancer
|
2011
|
0.94
|
|
34
|
Methylation-specific ligation detection reaction (msLDR): a new approach for multiplex evaluation of methylation patterns.
|
Mol Genet Genomics
|
2011
|
0.93
|
|
35
|
Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission.
|
Cancer Res
|
2003
|
0.93
|
|
36
|
Tuning tumor-specific T-cell activation: a matter of costimulation?
|
Trends Immunol
|
2002
|
0.92
|
|
37
|
Systematic comparative protein expression profiling of clear cell renal cell carcinoma: a pilot study based on the separation of tissue specimens by two-dimensional gel electrophoresis.
|
Mol Cell Proteomics
|
2009
|
0.92
|
|
38
|
Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation.
|
Clin Immunol
|
2011
|
0.91
|
|
39
|
Heat shock protein expression and anti-heat shock protein reactivity in renal cell carcinoma.
|
Proteomics
|
2002
|
0.91
|
|
40
|
High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma.
|
Cancer Res
|
2004
|
0.91
|
|
41
|
CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells.
|
Int J Cancer
|
2004
|
0.90
|
|
42
|
Monitoring peri-operative immune suppression in renal cancer patients.
|
Oncol Rep
|
2011
|
0.90
|
|
43
|
Identification of E2F1 as an important transcription factor for the regulation of tapasin expression.
|
J Biol Chem
|
2010
|
0.90
|
|
44
|
Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues.
|
Int J Cancer
|
2007
|
0.89
|
|
45
|
Heat shock proteins in renal cell carcinomas.
|
Contrib Nephrol
|
2005
|
0.88
|
|
46
|
Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses.
|
Biochim Biophys Acta
|
2003
|
0.88
|
|
47
|
Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer.
|
Cancer Res
|
2004
|
0.87
|
|
48
|
Cloning and functional analyses of the mouse tapasin promoter.
|
Immunogenetics
|
2003
|
0.87
|
|
49
|
Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors.
|
J Biol Chem
|
2013
|
0.86
|
|
50
|
Comparative expression profiling of distinct T cell subsets undergoing oxidative stress.
|
PLoS One
|
2012
|
0.85
|
|
51
|
Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response.
|
Hum Immunol
|
2003
|
0.85
|
|
52
|
Fast dendritic cells stimulated with alternative maturation mixtures induce polyfunctional and long-lasting activation of innate and adaptive effector cells with tumor-killing capabilities.
|
J Immunol
|
2013
|
0.84
|
|
53
|
Influence of Ki-ras-driven oncogenic transformation on the protein network of murine fibroblasts.
|
Proteomics
|
2007
|
0.84
|
|
54
|
HER-2/neu-mediated down-regulation of biglycan associated with altered growth properties.
|
J Biol Chem
|
2012
|
0.84
|
|
55
|
Functional cysteine-less subunits of the transporter associated with antigen processing (TAP1 and TAP2) by de novo gene assembly.
|
FEBS Lett
|
2003
|
0.84
|
|
56
|
Aminopeptidase N (APN)/CD13-dependent CXCR4 downregulation is associated with diminished cell migration, proliferation and invasion.
|
Mol Membr Biol
|
2008
|
0.83
|
|
57
|
Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer.
|
Cancer Immunol Immunother
|
2012
|
0.82
|
|
58
|
B7/CD28 costimulation of T cells induces a distinct proteome pattern.
|
Mol Cell Proteomics
|
2005
|
0.82
|
|
59
|
Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides.
|
Int J Cancer
|
2002
|
0.82
|
|
60
|
HLA-dependent tumour development: a role for tumour associate macrophages?
|
J Transl Med
|
2013
|
0.82
|
|
61
|
Regulation of beta1 integrin expression by PKCepsilon in renal cancer cells.
|
Int J Oncol
|
2004
|
0.81
|
|
62
|
CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells.
|
Arch Dermatol Res
|
2008
|
0.81
|
|
63
|
HER-2/neu mediates oncogenic transformation via altered CREB expression and function.
|
Mol Cancer Res
|
2013
|
0.80
|
|
64
|
The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma.
|
Cancer Immunol Immunother
|
2009
|
0.80
|
|
65
|
A proteomic view at T cell costimulation.
|
PLoS One
|
2012
|
0.80
|
|
66
|
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system.
|
Proteomics
|
2010
|
0.80
|
|
67
|
Impaired transporter associated with antigen processing (TAP) function attributable to a single amino acid alteration in the peptide TAP subunit TAP1.
|
J Immunol
|
2003
|
0.80
|
|
68
|
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.
|
J Transl Med
|
2014
|
0.80
|
|
69
|
Predominance of TH2 cells and plasma cells in polyoma virus nephropathy: a role for humoral immunity?
|
Hum Pathol
|
2012
|
0.79
|
|
70
|
The prognostic impact of human leukocyte antigen (HLA) class I antigen abnormalities in salivary gland cancer. A clinicopathological study of 288 cases.
|
Histopathology
|
2013
|
0.79
|
|
71
|
Comparative expression profiling for human endoplasmic reticulum-resident aminopeptidases 1 and 2 in normal kidney versus distinct renal cell carcinoma subtypes.
|
Int J Clin Exp Pathol
|
2013
|
0.79
|
|
72
|
Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors.
|
Cancer Res
|
2002
|
0.78
|
|
73
|
Promoter methylation of aminopeptidase N/CD13 in malignant melanoma.
|
Carcinogenesis
|
2012
|
0.78
|
|
74
|
High variation of individual soluble serum CD30 levels of pre-transplantation patients: sCD30 a feasible marker for prediction of kidney allograft rejection?
|
Nephrol Dial Transplant
|
2007
|
0.78
|
|
75
|
The role of HLA-G for protection of human renal cell-carcinoma cells from immune-mediated lysis: implications for immunotherapies.
|
Semin Cancer Biol
|
2003
|
0.78
|
|
76
|
Analysis of the structural integrity of the TAP2 gene in renal cell carcinoma.
|
Int J Oncol
|
2003
|
0.78
|
|
77
|
Predictive immunomonitoring -- the COST ENTIRE initiative.
|
Clin Immunol
|
2013
|
0.78
|
|
78
|
The non-classical antigens of HLA-G and HLA-E as diagnostic and prognostic biomarkers and as therapeutic targets in transplantation and tumors.
|
Clin Transpl
|
2013
|
0.78
|
|
79
|
"Tumor immunology meets oncology IV", 23rd and 24th May 2008 Martin Luther University Halle-Wittenberg, Halle, Germany.
|
Cancer Immunol Immunother
|
2008
|
0.77
|
|
80
|
Tumour immunity and T cell memory are induced by low dose inoculation with a non-replicating adenovirus encoding TAP1.
|
Vaccine
|
2006
|
0.77
|
|
81
|
Opposing consequences of signaling through EGF family members: Escape from CTLs could be a bait for NK cells.
|
Oncoimmunology
|
2012
|
0.77
|
|
82
|
Heterogeneous expression and functional relevance of the ubiquitin carboxyl-terminal hydrolase L1 in melanoma.
|
Int J Cancer
|
2013
|
0.77
|
|
83
|
B7-1 and B7-2 act differentially in the induction of a T cell response: their impact for a HLA-matched and HLA-mismatched anti-tumor immunotherapy.
|
Int J Cancer
|
2005
|
0.76
|
|
84
|
Impact of the mitogen-activated protein kinase pathway on the subproteome of detergent-resistant microdomains of colon carcinoma cells.
|
Proteomics
|
2015
|
0.75
|
|
85
|
"Tumor immunology meets oncology" (TIMO) X, May 23-24, 2014, Halle/Saale, Germany.
|
Cancer Immunol Immunother
|
2015
|
0.75
|
|
86
|
Adiponectin and Its Receptors Are Differentially Expressed in Human Tissues and Cell Lines of Distinct Origin.
|
Obes Facts
|
2017
|
0.75
|
|
87
|
Low frequency of HLA haplotype loss associated with loss of heterozygocity in chromosome region 6p21 in clear renal cell carcinomas.
|
Int J Cancer
|
2004
|
0.75
|
|
88
|
Correction: Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion.
|
Oncotarget
|
2017
|
0.75
|
|
89
|
"Tumor immunology meets oncology (TIMO) VI" from 7th to 8th of May 2010 in Halle, Germany.
|
Cancer Immunol Immunother
|
2010
|
0.75
|
|
90
|
"Tumor Immunology Meets Oncology (TIMO) VIII" from May 4 to 5, 2012, in Halle/Saale, Germany.
|
Cancer Immunol Immunother
|
2012
|
0.75
|